CharlesWRandallMD

PubMed

• 2 citations
  A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderatel...
  Matthieu Allez, Bruce E Sands, Brian G Feagan, Geert D'Haens, Gert De Hertogh, Charles W Randall, Bin Zou, Jewel Johanns, Christopher O'Brien, Mark Curran, Rory Rebuck...> ;Journal of Crohn's & Colitis. 2023 Aug 21
• 36 citations
  Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients W...
  William J. Sandborn, Bal R. Bhandari, Charles Randall, Ziad Younes, Tomasz Romanczyk, Yan Xin, Emily Wendt, Hao Chai, Matt McKevitt, Sally Zhao, John S. Sundy, Satish ...> ;Journal of Crohn's & Colitis. 2018 Aug 29
• 5 citations
  Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned.
  Anita Afzali, Matthew A. Ciorba, David A. Schwartz, Mai Sharaf, Chris Fourment, Timothy E. Ritter, Douglas C. Wolf, Ira Shafran, Charles Randall, Sunanda V. Kane> ;Inflammatory Bowel Diseases. 2018 Jan 1
• 14 citations
  Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials
  Edward V. Loftus, Jean-Frederic Colombel, Stefan Schreiber, Charles Randall, Miguel Regueiro, Tauseef Ali, C Arendt, Jason Coarse, Marshall Spearman, Gordana Kosutic> ;Clinical Gastroenterology and Hepatology. 2016 Dec 1
• 210 citations
  Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection
  Miguel Regueiro, Brian G. Feagan, Bin Zou, Jewel Johanns, Marion Blank, Marc Chevrier, S Plevy, John W. Popp, Freddy Cornillie, Milan Lukas, Silvio Danese, Paolo Gionc...> ;Gastroenterology. 2016 Jun 1
• 6 citations
  Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
  Scott D. Lee, David T. Rubin, William J. Sandborn, Charles Randall, Ziad Younes, Stefan Schreiber, David A. Schwartz, Robert Burakoff, David G. Binion, Themos Dassopou...> ;Inflammatory Bowel Diseases. 2016 Aug 1
• 23 citations
  Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiS...
  W J Sandborn, Gil Y. Melmed, Dermot P.B. McGovern, Edward V. Loftus, J. M. Choi, Judy H. Cho, Bincy Abraham, Alexandra Gutierrez, Gary R. Lichtenstein, Scott D. Lee, C...> ;Alimentary Pharmacology & Therapeutics. 2015 Aug 1
• 23 citations
  From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn’s disease
  Charles Randall, John Vizuete, Nicholas Martinez, John Alvarez, Karthik Garapati, Mazyar Malakouti, Carlo Taboada> ;Therapeutic Advances in Gastroenterology. 2015 Mar 16
• 52 citations
  Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study
  W J Sandborn, Scott D. Lee, Charles Randall, Alexandra Gutierrez, David A. Schwartz, Sumeet Ambarkhane, C. Kayhan, Bosny Pierre-Louis, Stefan Schreiber, Gary R. Lichte...> ;Alimentary Pharmacology & Therapeutics. 2014 Oct 1
• 114 citations
  Eluxadoline Benefits Patients With Irritable Bowel Syndrome With Diarrhea in a Phase 2 Study
  Leonard S. Dove, Anthony Lembo, Charles Randall, Ronald Fogel, David Andrae, J. Michael Davenport, Gail McIntyre, June Almenoff, Paul S. Covington> ;Gastroenterology. 2013 Aug 1
• 11 citations
  Current and emerging strategies in the management of Crohn's disease.
  Charles Randall, John Vizuete, Gregg Wendorf, Balaji Ayyar, Gregory Constantine> ;Best Practice & Research. Clinical Gastroenterology. 2012 Oct 1
• Join now to see all